AdAlta Ltd (ASX: 1AD) Share Price and News

Dr MacLeman has over 25 years of experience across all phases of the life sciences sector. With a career spanning veterinary practice, pharmaceutical development and manufacturing, biotechnology, diagnostics and finance, he has expertise in capital management, business development, technology commercialisation and sales & marketing globally. He has launched products using both in house and outsourced sales staff in Australia and the US. He has founded life sciences startups in the biologics area and worked in investment banking focusing on the analysis and financing of technology companies. He Chaired the Industry Review Committee for the Pharmaceutical Manufacturing National Training Package for the AISC for approximately 10 years prior to the establishment of the new Jobs and Skills Councils and advises the new formed Manufacturing Industry Skills Alliance. He is also an expert advisor to PharmaVentures plc. (Oxford, UK) and serves on a number of other NFP and government advisory groups.

Dr Oldham has more than 20 years of life sciences business development, alliance management, portfolio and product development, and commercialisation experience in Europe, Asia and Australia, with a particular focus on biologics, cell and gene therapies and pharmaceutical products. He was appointed CEO and MD in October 2019. Immediately prior to this, he was Executive Leader of Tijan Ventures, an advisory business focused on growing life sciences companies through strategic advisory and interim CEO, executive and nonexecutive leadership services, with a particular focus on biologics, cell and gene therapies and immunotherapy. Previous roles include CEO and Managing Director of Cell Therapies Pty Ltd, a leading contract manufacturer and distributor of cellular therapies in Asia Pacific, President of Asia Pacific for Hospira, Inc., and a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira.

Mr Diab is a corporate executive with more than 10 years of experience across financial institutions, technology transformation, operations, and investor relations. Mr Diab is currently the Managing Director of Phoenix Global Investments Pty Ltd. He also serves as a Non-Executive Director of Balkan Mining & Minerals Ltd (ASX: BMM) and formerly served as a Non-Executive Director of Advance Metals Limited (ASX: AVM) and Lithium Universe Ltd (ASX: LU7).

Ms Burke has more than 25 years of experience in the life sciences sector, with a breadth of knowledge across pharma and biotech industries, from earlystage development through to latestage commercialisation, across preIPO, private commercial, industry groups and multinational organisations. Her executive career as a commercial leader spanned more than two decades, including Bristol Myers Squibb and SmithKline Beecham. With her most recent focus on prelaunch, market access and payor negotiations, she has delivered market access, reimbursement and stakeholder leadership for products across multiple therapeutic areas, including oncology, haematology, immunology, virology, cardiovascular and metabolic conditions. She also led the New Zealand commercial business, launching key products in that market, and was business development lead for Australia and New Zealand. She is currently the industry nominee to the Pharmaceutical Benefits Advisory Committee, an independent statutory body that makes medicines decisions for inclusion to the Pharmaceutical Benefits Scheme (PBS). She is also Chair and nonexecutive director at Cell Therapies Pty Ltd (a leading contract development and manufacturer (CDMO) in cell and gene therapies). Other roles include non-executive director at Olivia Newton-John Cancer Research Institute, Senseye Australia Pty Ltd, as well as being past Chair of AusBiotech Ltd, the peak industry association for the life sciences sector. She also serves as an advisor for Proto Axiom Pty Ltd, an incubator for earlystage research commercialisation, and volunteers her expertise to other advisory boards.

-

-